GPP
BHVN

Great Point Partners’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Great Point Partners’s Portfolio BHVN Stock Details BHVN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-200,000
Closed -$8.76M – 48
2019
Q2 		$8.76M Hold
200,000
– – 0.97% 22
2019
Q1 		$10.3M Buy
+200,000
New +$8.64M 1.02% 26

Other funds holding BHVN

Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Stifel Financial
Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return
OIM
Oracle Investment Management Greenwich, Connecticut $168M AUM 42.86% 1-Year Est. Return
RM
RP Management New York $139M AUM 37.98% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Great Point Partners's BHVN Position: Q4 2020 in Review

Great Point Partners sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q4 2020, closing a stake of 435,000 shares — an estimated $28.3M sold.

Great Point Partners first reported a position in BHVN in Q4 2017 and held it in 5 quarters. The position peaked at $61.5M in Q2 2020. 238 funds tracked by Wall St. Rank hold BHVN as of Q4 2020.

  • Great Point Partners reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q4 2020 after selling out during the quarter.
  • Great Point Partners sold 435,000 Biohaven Pharmaceutical Holding Company Ltd. shares in Q4 2020, an estimated $28.3M.
  • Great Point Partners first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q4 2017 and held it in 5 quarters.
  • Great Point Partners's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $61.5M in Q2 2020.
  • 238 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q4 2020.

Based on Great Point Partners's 13F filing for Q4 2020, filed 16 Feb 2021.